Gilead developing tablet formulation of COVID drug remdesivir - CNBC
- BySeeking Alpha-
Gilead is testing a tablet form of its COVID-19 drug Veklury (remdesivir) , CNBC reports, adding it is in early stages.
Gilead is testing a tablet form of its COVID-19 drug Veklury (remdesivir) , CNBC reports, adding it is in early stages.
Gilead Sciences (pembrolizumab) is partnering with Merck to examine a combination of the former's Trodelvy with the latter's Keytruda (pembrolizumab) for first-line NSCLC.
Friday's top analyst upgrades and downgrades included Comerica, CrowdStrike, Exxon Mobil, Ford, Gilead Sciences, Goldman Sachs, Lowe's, Lyft and Palo Alto Networks.
Gilead Sciences, Inc. (GILD) is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used to treat diseases such as...
After its more than 450% surge during 2020, the meteoric rally in Moderna (NASDAQ:MRNA) shares continues this year. The gains—propelled by the biotech's breakthrough vaccine...
Vaccines manufactured by three groups have so far been approved in the UK. They include:AstraZeneca (LON:AZN) (NASDAQ:AZN)/ Oxford University;BioNTech (NASDAQ:BNTX) / Pfizer...
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Neutral | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Sell | Sell | Sell | Strong Buy | Strong Buy |
| Summary | Neutral | Neutral | Neutral | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 179.60 | 181.10 | 177.25 | +1.45 | +0.81% | 17.98M | London | |||
| 118.28 | 118.92 | 116.30 | +0.50 | +0.42% | 98.63M | London | |||
| 165.42 | 165.62 | 162.44 | -0.10 | -0.06% | 18.27M | London | |||
| 774.50 | 820.00 | 774.50 | -20.50 | -2.58% | 253.28K | London | |||
| 635.60 | 639.20 | 626.00 | +0.60 | +0.09% | 3.47M | London | |||
| 5.49 | 5.50 | 5.49 | 0.00 | 0.00% | 0.00 | London | |||
| 14.41 | 14.46 | 13.80 | 0.00 | 0.00% | 0.00 | London | |||
| 436.10 | 439.20 | 434.10 | -0.10 | -0.02% | 4.14M | London | |||
| 516.60 | 517.50 | 508.80 | +3.60 | +0.70% | 21.40M | London | |||
| 2,260.00 | 2,410.00 | 2,260.00 | -95.00 | -4.03% | 19.11K | London | |||
| 1.00 | 0.00 | 0.00 | 0.0000 | 0.00% | 4.68M | London | |||
| 443.00 | 450.00 | 450.00 | +3.00 | +0.68% | 38.50K | London | |||
| 43.68 | 45.36 | 43.60 | -1.80 | -3.96% | 1.53M | London | |||
| 0.195 | 0.00 | 0.00 | -0.0050 | -2.50% | 1.77M | London | |||
| 1,445.00 | 1,512.00 | 1,436.50 | -74.00 | -4.87% | 2.05M | London |